newsfilter
← Latest News
GlobeNewswire·

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

  • Iovance Biotherapeutics, Inc. granted inducement stock options on November 19, 2026, covering 175,840 shares of common stock to 22 new non-executive employees.
  • The awards were issued under the Company's Amended & Restated 2021 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
  • Each stock option carries an exercise price of $7.31, matching the closing stock price on the grant date.
  • Vesting occurs over a three-year period with one-third of shares vesting on the first anniversary of the employee's start date, while the remaining shares vest in eight quarterly installments over the subsequent two years.
  • Iovance operates as a global leader in tumor infiltrating lymphocyte (TIL) therapies, with its FDA-approved treatment Amtagvi® available in three markets at over 100 authorized treatment centers.
  • The Company maintains fully owned, centralized U.S.-based manufacturing scaled to serve thousands of cancer patients annually.
  • Iovance's product pipeline includes next-generation programs such as gene-edited TIL therapies, IL-12 tethered TIL therapies, next-generation IL-2, & precision immuno-oncology approaches.
Company
Iovance Biotherapeutics Inc
Keywords
Nasdaq:IOVA, Iovance Biotherapeutics Inc